Ovarian Cancer Drugs Market Share To Reach Scalable Heights Of Growth
Ovarian Cancer Drugs Industry The global ovarian cancer drugs market size is expected to reach USD 5.65 billion by 2030, registering a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market. Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe. Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies inclu...